GRI
GRI BioยทNASDAQ
--
--(--)
--
--(--)
GRI Profile
Gri Bio, Inc.
A clinical-stage biopharmaceutical company that develops novel drugs to deter abuse in the treatment of central nervous system disorders
2223 Avenida de la Playa, #208, La Jolla, CA 92037
--
GRI Bio, Inc., was incorporated under the laws of the State of Delaware on January 11, 2018. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for disorders associated with the immune response. Its lead product candidate, GRI-0621, is an oral inhibitor of iNKT cells under development for the treatment of idiopathic pulmonary fibrosis and other serious inflammatory and fibrotic diseases.
